Pharmaceuticals News

TORONTO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing,...

− Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses...

AMPLITUDE is the first clinical trial to evaluate potential therapies for patients with mHSPC and known HRR gene alterations, with positive results supporting the niraparib-based combination regimen...

Le CHMP recommande l'approbation du Rezurock de Sanofi dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte La recommandation s’appuie sur les résultats de sécurité et...

Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease Recommendation supported by safety and efficacy results from several clinical studies and real-world...

Immunocore announces R&D leadership evolution Dr. David Berman will depart the Company Dr. Mohammed Dar, Chief Medical Officer, and Mark Moyer, Head of Regulatory Sciences, promoted to Executive...

TONMYA demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study Unique sublingual formulation designed for bedtime dosing bypasses first-pass...

Fourth quarter 2025 revenues increased 3% to $3.9 billion versus fourth quarter 2024; full year 2025 revenues increased 1% to $14.3 billion versus 2024Fourth quarter 2025 Dupixent® global net sales...

THE WOODLANDS, Texas, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the pricing of its previously announced underwritten public offering...

ORION OYJ                LEHDISTÖTIEDOTE 30.1.2026 KLO 9.30          Orion julkaisee tilinpäätöstiedotteen vuodelta 2025 ja järjestää verkkolähetyksen 12.2.2026 Orion julkaisee...